SCHEMBL6519121

SCHEMBL6519121

O=c1[nH]c2ncccc2c2cc(NCc3cccc4ccccc34)ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.55
PARP1 P09874 1/20 0.55
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
PIK3CB P42338 5/20 0.44
PIK3CA P42336 4/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
FYN P06241 1/20 0.41
SRC P12931 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CG P48736 1/20 0.41
VCP P55072 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
IDH1 O75874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3453866 0.86 AURKA (0.55) AURKAPARP1LMNAMAPTMEN1
SCHEMBL6521905 0.86 AURKA (0.55) AURKAPARP1ALDH1A1LMNAMAPT
SCHEMBL6525348 0.86 AURKA (0.55) AURKAPARP1MAPTVCP
SCHEMBL3455169 0.86 AURKA (0.55) AURKAPARP1MAPTCYP3A4CYP2C9
SCHEMBL3454715 0.86 AURKA (0.55) AURKAPARP1ALDH1A1MAPTCYP3A4
SCHEMBL12846643 0.84 AURKA (0.52) AURKAPARP1ALDH1A1LMNAMAPT
SCHEMBL3453920 0.83 CDC7 (0.53) AURKAPARP1MAPTCYP3A4SRC
SCHEMBL6518864 0.83 AURKA (0.51) AURKAPARP1CYP3A4MEN1KMT2A
SCHEMBL6518393 0.83 AURKA (0.51) AURKAPARP1IDH1
SCHEMBL3454371 0.83 AURKA (0.60) AURKAPARP1FYNSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885PARP1 1693/4885ALDH1A1 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.